Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance

Inclusion criteria

• Age 18-75 years old.
• LDL-C≥3.4mmol/l (130 mg/dL).
• Glycosylated hemoglobin ≤ 6.0% (42 mmol/mol).
• Voluntarily sign informed consent.

Exclusion criteria

• Previous diagnosis of diabetes or prediabetes.
• Past or current use of hypoglycemic drugs.
• Oral administration of statin lipid-lowering drugs within three months before enrollment.
• Combined oral drug quantity ≥3.
• History of ASCVD (previous myocardial infarction, ACS, stroke or TIA within 1 year, symptomatic peripheral vascular disease).
• Active liver disease (defined as elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) >2 × upper limit of normal (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.
• Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.
• Estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method
• New York Heart Association (NYHA) Class IV heart failure or a known left ventricular ejection fraction < 25%
• A clinically significant and drug- or ablation-resistant arrhythmia within 3 months prior to randomization
• An acute or severe systemic infection, or any of the following diseases: hematological disorders, autoimmune disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status
• Scheduled for surgery within 6 months
• Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion
• Subjects with alcohol or other drug addiction
• Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome
• A history of allergic reaction to any study drug or its excipients or similar chemical classes of drugs
• A family history of homozygous familial hypercholesterolemia
• Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up
• Any condition that the investigator considers unsuitable for participation.